Authors
Latest:
PI3K Inhibitors for CLLA comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.
Latest:
Unmet Needs in SM TreatmentThe panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.
Latest:
Trainees Deserve Better FeedbackFeedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.
Latest:
Comprehensive Treatment Advances Care for Patients With Early-Stage Breast CancerAdvances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.
Latest:
Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple MyelomaDickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.
Latest:
Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in LymphomaIra Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.
Latest:
The Future of Breast Cancer Surgery Is HereThanks to advances in research, targeted therapies, and a more personalized approach to treating patients diagnosed with breast cancer, more surgical options exist for patients with breast cancer patients than ever before.
Latest:
Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIsAmanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.
Latest:
NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion MutationsBefore closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.
Latest:
Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract CancerMojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.
Latest:
Dr. Massarelli on Unmet Needs in EGFR Exon 20–Mutated NSCLCErminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.
Latest:
Beyond the Clinic: Leveraging Research to Tackle Lung Cancer DisparitiesLung cancer remains the most common cause of cancer death in the United States.
Latest:
Dr. Mark on Questions Regarding Sequencing in Multiple MyelomaTomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.
Latest:
Clinical Pearls and the Future of LEMSExperts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.
Latest:
Dr. Venkat on Unmet Needs in Ovarian CancerPuja S. Venkat, MD, discusses unmet needs in ovarian cancer.
Latest:
Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLCYasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.
Latest:
Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPCBilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.
Latest:
Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETsNitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
Dr. Weiss on Selecting Optimal Radiation Therapy for Brain MetastasesStephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.
Latest:
Dr. Mahal on the Emerging Role of Epigenomics in Prostate CancerBrandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.
Latest:
The COVID-19 Pandemic Will Have Long-Term Impact on Oncology PracticesThe COVID-19 pandemic created new patient care challenges in oncology, such as how to reduce risks of virus exposure for patients who may be immunocompromised and switching from in-person visits to telemedicine.
Latest:
Cleveland Clinic Appoints J. Joseph Melenhorst, PhD as Director of Cell Therapy and Immuno-Engineering Program, and Vice Chair of Center for Immunotherapy and Precision Immuno-OncologyJ. Joseph Melenhorst, Ph.D., has been appointed director of the new Cell Therapy and Immuno-Engineering Program, and Vice Chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.
Latest:
Real-World Evidence on Use of Immune Checkpoint Inhibitor Combinations and Clinical Trial EndpointsExperts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.
Latest:
Dr. Neumann on Tapering Steroids in cGVHDJoyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.
Latest:
Question and Answer SessionDr Gary Ulaner and Dr Jeremy Force answer questions submitted by attendees of the live webinar discussing the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18-F FES-PET imaging in diagnosis and treatment of ER-positive breast cancer.
Latest:
Women in Oncology: Prioritization and Passionate LegaciesSelina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Latest:
Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple MyelomaLaura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.
Latest:
First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet RegimensAn expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.
